Inozyme Pharma EBIT

Inozyme Pharma posts a EBIT of $-100M as of March 2025. That compares with $-82M in the prior-year period — down 28.0% year over year. That is below the Healthcare sector average of $23B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Inozyme Pharma's EBIT was $-82M. The latest reading is $-100M — a 28.0% year-over-year decrease (period ending March 2025). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a EBIT near $23B is typical. Inozyme Pharma's $-100M is lower that level. That is roughly 100.5% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Inozyme Pharma's financial statement story. At $-100M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for INZY's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $23B), and (3) consistency with growth and profitability. This page covers the first two; Inozyme Pharma's other metric pages and overview cover the third.